The influence of maternal immunity on the efficacy of a classical swine fever vaccine against classical swine fever virus, genogroup 2.2, infection
The influence of maternal immunity on the efficacy of a classical swine fever vaccine against classical swine fever virus, genogroup 2.2, infection
复制标题
DOI：
10.1016/s0378-1135(02)00357-7
复制
发表时间：
2003-03-20
影响因子：
3.3
通讯作者：
Damrongwatanapokin, S
中科院分区：
文献类型：
--
作者：
Suradhat, S;Damrongwatanapokin, S
在常规接种疫苗的泰国，在过去十年中，慢性经典猪瘟（CSF）暴发的发病率有所增加。主要的致病病毒已被确定为2.2基因组的中等毒力的经典猪瘟病毒（CSFV）。对一种脑脊液疫苗对抗2.2基因群攻击的有效性进行了调查。5周龄猪按被动抗体滴度分组，接种中国猪瘟毒株疫苗，接种后13 d用猪瘟病毒2.2基因组攻毒。免疫时被动滴度低于64的组，具有明显更高的csfv特异性ifn - γ分泌细胞数量，完全免受攻击。有趣的是，较高的被动滴度抑制了猪的细胞和抗体反应。此外，攻毒后，该组50%的猪可分离出猪瘟病毒。结果表明，在接种时母源性滴度低于64的条件下，CSF疫苗可诱导猪完全保护。结果表明，猪瘟暴发的增加可能是由于接种时间不适当以及猪瘟基因群的性质所致。(C) 2002 Elsevier Science B.V.版权所有
In Thailand, where vaccination is routinely employed, there has been an increased incidence of chronic classical swine fever (CSF) outbreaks during the past decade. The major causative virus has been identified to be the moderate virulence, classical swine fever virus (CSFV) of the genogroup 2.2. An investigation was made into the efficacy of a CSF vaccine against this genogroup 2.2 challenge. Five-week-old pigs, grouped by their level of passive antibody titer were immunized with lapinized Chinese-strain CSF vaccine and challenged with CSFV genogroup 2.2, 13 days after vaccination. The group containing passive titers of lower than 64 at the time of immunization, had significantly higher number of CSFV-specific IFN-gamma secreting cells and was completely protected against the challenge. Interestingly, both cellular and antibody responses were inhibited in the pigs with the higher passive titer. Furthermore, following challenge, CSFV could be isolated from 50% of the pigs in this group. It was demonstrated that the CSF vaccine could induce complete protection in pigs, provided that the maternal derived titer at the time of vaccination was lower than 64. The result implied that an increase in CSFV outbreaks might be due to the inappropriate timing of vaccination as well as the nature of the CSFV genogroup 2.2. (C) 2002 Elsevier Science B.V. All rights reserved.